These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
710 related articles for article (PubMed ID: 30628518)
21. Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series. Slodownik D; Levi A; Lapidoth M; Moshe S Dermatology; 2022; 238(6):1073-1075. PubMed ID: 35462358 [TBL] [Abstract][Full Text] [Related]
22. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study. Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676 [TBL] [Abstract][Full Text] [Related]
23. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972 [TBL] [Abstract][Full Text] [Related]
24. Dupilumab for atopic dermatitis: evidence to date. Rodrigues MA; Nogueira M; Torres T G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470 [TBL] [Abstract][Full Text] [Related]
25. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients. Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603 [TBL] [Abstract][Full Text] [Related]
26. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798 [TBL] [Abstract][Full Text] [Related]
27. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis. Stout M; Silverberg JI J Am Acad Dermatol; 2019 Jul; 81(1):157-162. PubMed ID: 30885752 [TBL] [Abstract][Full Text] [Related]
28. Safety of dupilumab in patients with atopic dermatitis: expert opinion. Francuzik W; Alexiou A; Worm M Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910 [No Abstract] [Full Text] [Related]
29. Contact dermatitis and atopic dermatitis: two tales, an interwoven story. Holmes GA; Vassantachart JM; Sung CT; Goldenberg A; Jacob SE G Ital Dermatol Venereol; 2019 Aug; 154(4):425-434. PubMed ID: 30428660 [TBL] [Abstract][Full Text] [Related]
30. Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: Retrospective chart analysis from a single tertiary care center. Parmar NV; Abdula MA; Al Falasi A; Krishna CV Dermatol Ther; 2022 May; 35(5):e15415. PubMed ID: 35238115 [TBL] [Abstract][Full Text] [Related]
31. Dupilumab: A review of its use in the treatment of atopic dermatitis. Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919 [TBL] [Abstract][Full Text] [Related]
32. Dupilumab facial redness: Clinical characteristics and proposed treatment in a cohort. Ordóñez-Rubiano MF; Casas M; Balaguera-Orjuela V Dermatol Ther; 2021 Nov; 34(6):e15140. PubMed ID: 34549488 [TBL] [Abstract][Full Text] [Related]
33. The use of selective Th2 blocker dupilumab for the treatment of atopic dermatitis in a heart transplant patient: Case report. Sklover L; Nielson C; De Benedetto A Dermatol Ther; 2019 Nov; 32(6):e13144. PubMed ID: 31664753 [TBL] [Abstract][Full Text] [Related]
34. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. Ariëns LFM; van der Schaft J; Spekhorst LS; Bakker DS; Romeijn GLE; Kouwenhoven TA; Kamsteeg M; Voorberg AN; Oosting AJ; de Ridder I; Sloeserwij A; Haeck I; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS J Am Acad Dermatol; 2021 Apr; 84(4):1000-1009. PubMed ID: 32946967 [TBL] [Abstract][Full Text] [Related]
35. Dupilumab for treatment of atopic dermatitis. Seegräber M; Srour J; Walter A; Knop M; Wollenberg A Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246 [TBL] [Abstract][Full Text] [Related]
36. Patch Testing in a Patient on Dupilumab. Hoot JW; Douglas JD; Falo LD Dermatitis; 2018; 29(3):164. PubMed ID: 29570490 [No Abstract] [Full Text] [Related]
37. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. Hendricks AJ; Yosipovitch G; Shi VY J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426 [No Abstract] [Full Text] [Related]
38. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. Treister AD; Kraff-Cooper C; Lio PA JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653 [TBL] [Abstract][Full Text] [Related]
39. Drug evaluation review: dupilumab in atopic dermatitis. Hamilton JD; Ungar B; Guttman-Yassky E Immunotherapy; 2015; 7(10):1043-58. PubMed ID: 26598956 [TBL] [Abstract][Full Text] [Related]
40. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. Thyssen JP; de Bruin-Weller MS; Paller AS; Leshem YA; Vestergaard C; Deleuran M; Drucker AM; Foelster-Holst R; Traidl-Hoffmann C; Eyerich K; Taieb A; Su JC; Bieber T; Cork MJ; Eichenfield LF; Guttman-Yassky E; Wollenberg A J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1224-1231. PubMed ID: 31056788 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]